Hexarelin vs Ipamorelin

Shared Mechanism

Both peptides are synthetic growth hormone-releasing peptides (GHRPs) that act on the growth hormone secretagogue receptor (GHS-R1a) in the anterior pituitary and hypothalamus. Activation of this receptor mimics endogenous ghrelin signaling and stimulates pulsatile GH release that follows the body's natural rhythms.

Because they share a receptor target, both produce a comparable peak in plasma GH within roughly fifteen to thirty minutes of administration in research models. The differences appear in selectivity, downstream signaling, and the magnitude and duration of the response.

Hexarelin: Potency and Cross-Reactivity

Hexarelin is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) developed in the 1990s as one of the more potent first-generation GHRPs. It produces a strong GH pulse and has been studied extensively for cardiovascular effects via CD36 receptor interactions in cardiac tissue.

The trade-off for that potency is reduced selectivity. Hexarelin also elevates cortisol and prolactin in many research models, and chronic dosing studies report meaningful desensitization of the GHS-R1a receptor — effects that complicate interpretation of long-running protocols.

Ipamorelin: Selectivity and Clean Profile

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide engineered specifically to release GH without measurable changes in cortisol, prolactin, ACTH, or aldosterone at standard research doses. This 'clean' selectivity profile is its defining feature.

Its GH pulse is smaller in absolute magnitude than Hexarelin's, but the relative absence of off-target endocrine effects makes it a preferred tool when the research question is GH-specific and confounding by the HPA axis must be minimized.

GH Release Profile — Side by Side

Hexarelin produces a higher peak GH amplitude per dose and, in some models, a slightly longer-lasting elevation, but at the cost of receptor desensitization within days of repeated administration.

Ipamorelin produces a lower but more reproducible peak across consecutive dosing periods. Pulses remain consistent over extended dosing windows in animal models, which makes Ipamorelin the better choice for time-course studies where each pulse must be comparable to the last.

Research Applications

Hexarelin is most often used in research that examines the upper bound of GH secretory capacity, cardioprotective signaling, or CD36-mediated pathways. Its potency suits short-duration challenge studies.

Ipamorelin is favored in studies of GH pulsatility, longitudinal GH/IGF-1 dynamics, and any protocol where prolactin or cortisol noise would confound the readout. It is also commonly paired with a GHRH analog such as CJC-1295 in dual-agonist research protocols.

Handling and Stability

Both peptides are supplied as lyophilized powder, reconstituted with bacteriostatic water, and stored at 2–8°C after reconstitution. Both are sensitive to repeated freeze-thaw cycles. Aliquot before freezing, and document lot, concentration, and date with every aliquot.